Zacks Investment Research·Jun 22, 2026
Why Steris (STE) is a Top Growth Stock for the Long-TermWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
STERIS plc(STE)Earnings, Financials & Key Ratios
STE•NYSE
$212.30
26.8× P/E·Price updated Jul 7, 2026
AboutSTERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and powered dental instruments, infection control products, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.Show more
- Revenue$5.94B+8.7%
- EBITDA$1.1B-18.0%
- Net Income$785M+27.7%
- EPS (Diluted)7.93+27.9%
- Gross Margin44.25%+0.5%
- EBITDA Margin18.56%-24.5%
- Operating Margin18.56%+16.9%
- Net Margin13.23%+17.5%
- ROE11.37%+19.6%
STE Price & Volume
STERIS plc (STE) stock price & volume — 10-year historical chart
Loading chart...
Resilient Service Model Offsets Regulatory Compliance Costs
Investment Thesis • Updated 2026Q4
VerdictNeutral
Growth:Stable
Profitability:Moderate
Financial:Healthy
Cash Flow:Robust
Primary Risk:Regulatory EO compliance costs
Key Thesis Takeaways
- STERIS demonstrates a durable growth profile underpinned by a recurring revenue model that effectively mitigates capital equipment volatility, as evidenced by a 7.3% year-over-year revenue increase in 2026Q4.
- While the company has successfully deleveraged its balance sheet, reducing total debt to $1.9 billion, investors should monitor the potential margin compression stemming from ongoing regulatory compliance requirements in the AST segment.
- The firm's ability to maintain a 19.9% operating margin while navigating these capital-intensive mandates remains a critical factor for long-term valuation sustainability.
Verdict Logic
while the company maintains a robust liquidity position with a current ratio of 2.09, the forward P/E of 21.15 and potential regulatory expenditure risks warrant a cautious approach to valuation.
STE Growth Metrics
STERIS plc (STE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years10.24%
5 Years13.82%
3 Years9.38%
TTM8.73%
Profit CAGR
10 Years21.63%
5 Years14.59%
3 Years94.3%
TTM27.29%
EPS CAGR
10 Years17.66%
5 Years11.36%
3 Years94.97%
TTM27.9%
Return on Capital
10 Years8.6%
5 Years8.52%
3 Years9.7%
Last Year11.77%
STE Recent Earnings
STERIS plc (STE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$2.83-0.7%
$2.85
Rev
$1.6B-0.4%
$1.6B
Q1 2026
Feb 4, 2026Metric
Actual
Est
EPS
$2.53+0.0%
$2.53
Rev
$1.5B+1.0%
$1.5B
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$2.47+5.1%
$2.35
Rev
$1.5B+2.0%
$1.4B
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$2.34+3.5%
$2.26
Rev
$1.4B+2.1%
$1.4B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $2.83vs $2.85-0.7% | $1.6Bvs $1.6B-0.4% |
| Q1 2026 | Feb 4, 2026 | $2.53vs $2.53+0.0% | $1.5Bvs $1.5B+1.0% |
| Q4 2025 | Nov 5, 2025 | $2.47vs $2.35+5.1% | $1.5Bvs $1.4B+2.0% |
| Q3 2025 | Aug 6, 2025 | $2.34vs $2.26+3.5% | $1.4Bvs $1.4B+2.1% |
Based on last 12 quarters of dataView full earnings history →
Latest STE News
Recent stock market news and headlines for STERIS plc (STE)
Peers Comparison
Key metrics vs top competitors for STERIS plc (STE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $212.30 | $20.84B | 26.77 | 8.73% | 13.23% | 11.37% | 1.15% | |
| $374.93 | $24.44B | 34.84 | 6.99% | 11.91% | 8.04% | — | |
| $72.14 | $4.3B | 33.87 | 11.66% | 9.03% | 8.95% | — | |
| $86.84 | $9.89B | 26.56 | 4.03% | 2.95% | 8.14% | — | |
| $17.46 | $1.36B | -2.59 | 1.53% | -30.15% | -47.65% | — | |
| $34.24 | $1.06B | 22.68 | 5.16% | 4% | 5.4% | — |
Compare STE vs Peers
STERIS plc (STE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
STE SEC Filings & Documents
STERIS plc (STE) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Apr 6, 2026·SEC
10-K Annual Reports
210-Q Quarterly Reports
6Get notified when STE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
STE Frequently Asked Questions
STERIS plc (STE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is STERIS plc's revenue?
STERIS plc (STE) reported $5.94B in revenue for fiscal year 2026. This represents a 910% increase from $587.9M in 1997.
How fast is STERIS plc growing?
STERIS plc (STE) grew revenue by 8.7% over the past year. This is steady growth.
Is STE profitable?
Yes, STERIS plc (STE) is profitable, generating $782.4M in net income for fiscal year 2026 (13.2% net margin).
Dividend & Returns
Does STE pay dividends?
Yes, STERIS plc (STE) pays a dividend with a yield of 1.15%. This makes it attractive for income-focused investors.
What is STE's return on equity?
STERIS plc (STE) has a return on equity (ROE) of 11.4%. This is reasonable for most industries.
What is STERIS plc's free cash flow?
STERIS plc (STE) generated $972.4M in free cash flow for fiscal year 2026. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.